Wednesday, March 18, 2015 8:22:57 AM
Quote:
________________________________________
GEN News HighlightsMore »
Nov 6, 2014
Aeterna Zentaris Ponders Macrilen's Future after FDA Setback
Aeterna Zentaris said today it is assessing the future of its registrational adult growth hormone deficiency (AGHD) treatment MacrilenTM (macimorelin) after receiving a Complete Response Letter from the FDA.
The FDA told Aeterna Zentaris its NDA for Macrilen cannot be approved in its present form. The agency cited concerns about data from the company’s Phase III pivotal trial of the drug candidate, the company added.
"Following the FDA's decision, we are currently reviewing the outstanding issues stated in the CRL in order to evaluate our options and future plans for Macrilen," David Dodd, Aeterna Zentaris’ chairman and CEO, said in a statement.
Macrilen is an orally-active ghrelin agonist designed to stimulate the secretion of growth hormone. The compound has been granted orphan drug designation by the FDA for AGHD.
In its Complete Response Letter, the FDA said the planned analysis of the pivotal trial did not meet its stated primary efficacy objective as agreed to in a Special Protocol Assessment agreement between the company and the agency.
The letter also cited issues related to what it said was the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD.
"In light of the failed primary analysis and data deficiencies noted, the clinical trial does not by itself support the indication," the FDA stated in its letter, according to Aeterna Zentaris.
To address the deficiencies it identified, the FDA added, Aeterna Zentaris will need to demonstrate the efficacy of macimorelin as a diagnostic test for growth hormone deficiency in a new, confirmatory clinical study.
The letter also outlined that a serious event of electrocardiogram QT interval prolongation occurred, for which attribution to drug could not be excluded. Therefore a dedicated thorough QT study to evaluate the effect of macimorelin on the QT interval would be necessary.
The FDA complete response letter marks Aeterna Zentaris’ latest setback over the past nearly two years. In June, the company disclosed plans to slice its workforce to 65 staffers from the 90 it employed at the start of 2014—part of a “resources optimization program” that Dodd said was intended to “streamline our operations, optimize our resources and R&D productivity, reduce our operating cash burn and more appropriately, align our financial resources with our strategic goal of transitioning into a commercially operating specialty biopharmaceutical company.”
Last year, Aeterna Zentaris halted a Phase III trial that assessed perifosine in combination with bortezomib (Velcade®) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. The company cited the recommendation of the study’s independent data safety monitoring board, which concluded it was highly unlikely the study would achieve a significant difference in its primary endpoint, progression free survival. According to the company, no safety concerns were raised.
____________________________________
http://www.genengnews.com/gen-news-highlights/aeterna-zentaris-ponders-macrilen-s-future-after-fda-setback/81250566/
AEZS
Recent CSCI News
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 09/06/2024 06:04:41 PM
- COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 08/27/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:36 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 12:05:17 PM
- COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/13/2024 12:05:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM